Bayer and Ardea in Cancer Drug Deal
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)
Published: 29 Apr-2009
DOI: 10.3833/pdr.v2009.i4.1101 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bayer has entered into a global agreement with San Francisco-based Ardea Biosciences focused on the development of mitogen-activated ERK kinase inhibitors for the treatment of solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS